IMP-3 Monoclonal Antibody

The protein encoded by this gene is primarily found in the nucleolus, where it can bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may repress translation of insulin-like growth factor II during late development. The encoded protein contains several KH domains, which are important in RNA binding and are known to be involved in RNA synthesis and metabolism. A pseudogene exists on chromosome 7, and there are putative pseudogenes on other chromosomes.

The IMP-3 Monoclonal Antibody is a highly specialized product that has been developed to target and bind to the IMP-3 protein. This protein is known to be overexpressed in a variety of cancer cells, making it an important target for cancer therapy. The IMP-3 Monoclonal Antibody has been rigorously tested and validated for its specificity and efficacy in binding to the IMP-3 protein, making it a reliable tool for cancer research and treatment.

This product is manufactured using state-of-the-art technology and quality control measures to ensure its purity and consistency. It is available in a variety of formats, including purified antibody, conjugated antibody, and recombinant protein, to suit the specific needs of researchers and clinicians.

The IMP-3 Monoclonal Antibody has been extensively studied in preclinical and clinical trials, demonstrating its potential as a therapeutic agent for various types of cancer. Its ability to selectively target cancer cells while sparing normal cells makes it a promising candidate for cancer immunotherapy.

In summary, the IMP-3 Monoclonal Antibody is a highly specialized and reliable product that has been developed to target the IMP-3 protein, a key player in cancer development and progression. Its specificity and efficacy make it a valuable tool for cancer research and treatment, and its potential as a therapeutic agent holds great promise for the future of cancer immunotherapy.